Holen Sie sich die Stockscreener-App
32.02
2.94%
-0.97
Handel nachbörslich:
32.02
Schlusskurs vom Vortag:
$32.99
Offen:
$33.08
24-Stunden-Volumen:
597.64K
Relative Volume:
0.82
Marktkapitalisierung:
$2.25B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-195.21M
KGV:
-10.08
EPS:
-3.1763
Netto-Cashflow:
$-176.19M
1W Leistung:
-11.96%
1M Leistung:
-13.99%
6M Leistung:
+22.45%
1J Leistung:
+30.27%
1-Tages-Spanne:
$31.96
$33.62
1-Wochen-Bereich:
$31.91
$36.88
52-Wochen-Spanne:
$20.65
$43.25
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
32.02 | 2.25B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Form 4 Pharvaris N.V. For: 26 September - Investing.com India
Trade Alert: Independent & Non-Executive Vice Chairman Of Pharvaris Hans J. G. C. Schikan Has Sold Stock - webull.com
A Pharvaris (PHVS) director proposes selling shares valued at $395,524. - Stock Titan
Form 4 Pharvaris N.V. For: 23 September - Investing.com India
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com Nigeria
(PHVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Planned $7M Pharvaris (NASDAQ: PHVS) stock sale disclosed for founder shares - Stock Titan
After $7M stock sale, Pharvaris (NASDAQ: PHVS) director plans more - Stock Titan
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade - Eastern Progress
Form 4 Pharvaris N.V. For: 22 September By Investing.com - Investing.com India
Pharvaris (PHVS) Insider Trading Activity 2026 - MarketBeat
Pharvaris (NASDAQ: PHVS) officer plans Rule 144 sale of 6,000 shares - Stock Titan
Pharvaris (PHVS) CEO buys 300,000 shares in rights exercise - Stock Titan
Pharvaris Chief Early Development Anne Lesage disposes of USD 765,466 in common shares - Bitget
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Australia
Glassman Robert Executes Option Exercise and Sells 8,667 Pharvaris Shares on September 15, 2026 - Kalkine Media
Pharvaris N.V. (PHVS) Stock Analysis: Biotech Innovator With A 53.58% Potential Upside - DirectorsTalk Interviews
Pharvaris (NASDAQ: PHVS) officer to sell 100,000 shares under Rule 144 - Stock Titan
Shareholder at Pharvaris (NASDAQ: PHVS) plans multi-million-dollar stock sale - Stock Titan
Pharvaris (NASDAQ: PHVS) lines up $10.5M sale of founder stock - Stock Titan
Pharvaris (NASDAQ: PHVS) director plans nearly $2M stock sale in 2026 - Stock Titan
Founder shares in Pharvaris (NASDAQ: PHVS) set for $765K planned sale - Stock Titan
Pharvaris (NASDAQ: PHVS) director lines up new stock sale after recent trades - Stock Titan
Pharvaris N.V. (PHVS) exec sells 46,400 shares in cashless trade - Stock Titan
Souverijns Wim Executes Option Exercises and Sells 26,090 Pharvaris Shares - Kalkine Media
Pharvaris N.V. (PHVS) Edges Higher as Shares Test Resistance Near $40Strangle Setup - careplusvn.com
Pharvaris at H.C. Wainwright conference: dual HAE push gains pace By Investing.com - Investing.com Nigeria
Pharvaris at H.C. Wainwright conference: dual HAE push gains pace - Investing.com
Officer at Pharvaris (NASDAQ: PHVS) plans potential $1.77M stock sale - Stock Titan
Pharvaris (NASDAQ: PHVS) CEO sells 2,291 shares in 10b5-1 plan trade - Stock Titan
PHVS Stock Rises 10% in a Month: What Is Driving the Rally? - Eastern Progress
Pharvaris at Morgan Stanley conference: oral HAE drug nears launch By Investing.com - Investing.com Nigeria
Pharvaris at Morgan Stanley conference: oral HAE drug nears launch - Investing.com
Pharvaris (NASDAQ: PHVS) exec files to sell shares from vested stock and options - Stock Titan
2,291 Pharvaris (Nasdaq: PHVS) shares set for resale - Stock Titan
Cantor Fitzgerald reiterates Pharvaris stock rating after trial data By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Pharvaris stock rating after trial data - Investing.com
(PHVS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Pharvaris Soars on Breakthrough Trial Win and Lofty Targets - TipRanks
Pharvaris Director Robert Glassman Executes 8,000-Share Sale via Rule 10b5-1 Plan - Kalkine Media
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win? - Yahoo Finance
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2026-09-10 - Seeking Alpha
Pharvaris (NASDAQ: PHVS) officer to sell 30,000 shares in September 2026 - Stock Titan
Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum By Investing.com - Investing.com India
Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum - investing.com
PHVS Maintained by Guggenheim -- Price Target Raised to $44.00 - GuruFocus
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com Nigeria
Guggenheim raises Pharvaris stock price target on trial results - Investing.com
Pharvaris at Wells Fargo conference: oral HAE drug gains ground By Investing.com - Investing.com India
Pharvaris at Wells Fargo conference: oral HAE drug gains ground - investing.com
symbol__ Stock Quote Price and Forecast - CNN
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):